{"id":"NCT01608815","sponsor":"Sanofi Pasteur, a Sanofi Company","briefTitle":"Study of a Single Dose of SP093 Typhoid Vi Polysaccharide Vaccine in Japanese Subjects","officialTitle":"Immunogenicity and Safety of a Single Dose of SP093 Typhoid Vi Polysaccharide Vaccine Given in Japanese Subjects","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-05","primaryCompletion":"2012-09","completion":"2012-12","firstPosted":"2012-05-31","resultsPosted":"2014-05-12","lastUpdate":"2014-05-12"},"enrollment":200,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Salmonella Infections","Typhoid Fever","Bacterial Infections"],"interventions":[{"type":"BIOLOGICAL","name":"Typhoid Vi polysaccharide","otherNames":["Typhim Vi"]}],"arms":[{"label":"Study Group","type":"EXPERIMENTAL"}],"summary":"This study is designed to assess the immunogenicity and safety of typhoid Vi polysaccharide vaccine in Japanese participants to support registration of the product in Japan.\n\nPrimary Objective:\n\nTo describe the seroconversion rate (percentage of subjects with at least a 4-fold increase of their Vi antibody titer) between Day 0 before vaccination and Day 28 after vaccination with typhoid Vi polysaccharide (SP093) vaccine in subjects aged 2 years and above.\n\nSecondary Objectives:\n\n* To describe the safety profile of a single dose of typhoid Vi polysaccharide vaccine up to 28 days after vaccination, in subjects aged 2 years and above.\n* To describe the immune response following a single dose of typhoid Vi polysaccharide vaccine in subjects aged 2 years and above.","primaryOutcome":{"measure":"Number of Participants With At Least a 4-Fold Rise in Vi Antibody Titers Following Vaccination With a Typhoid Vi Polysaccharide Vaccine","timeFrame":"Day 0 (pre-vaccination) to Day 28 (post-vaccination)","effectByArm":[{"arm":"Adults (Group 1)","deltaMin":173,"sd":null},{"arm":"Dolescents (Group 2)","deltaMin":6,"sd":null},{"arm":"Children (Group 3)","deltaMin":5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":4,"exclusionCount":19},"locations":{"siteCount":3,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":["http://www.sanofipasteur.com"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":188},"commonTop":["Injection site Pain","Myalgia","Malaise","Headache","Nasopharyngitis"]}}